Resources Archive - Page 4 of 47

Discovery of a Novel CD39 Inhibitor by DEL Screening

The ATP-adenosine pathway plays a crucial role in regulating immune responses, including those involved in combating tumors. CD39 is an...

Key Steps in Validating Targeted Protein Degraders

Choose excellence, choose WuXi Biology – your reliable partner in Targeted Protein Degradation (TPD) drug discovery. Since 2016, we have...

OncoWuXi Express: Animal Models of Parkinson’s Disease

Introduction： OncoWuXi Express will continue to keep you informed about updates to our online pharmacology model database (OncoWuXi Database), as...

ADC Development: Preclinical Pharmacology Essentials

Antibody-drug conjugates (ADCs) are increasingly demonstrating their value in cancer treatment, especially in combination therapies and for targeting resistant cancer...

Targeted Protein Degraders: Trends, Challenges, and Solutions

Since 2016, WuXi AppTec has built a comprehensive discovery platform focused on Targeted Protein Degraders (TPDs). Our platform enables research...

Innovative R&D Strategies for Peptide Drugs in Obesity Treatment

Introduction: Obesity has emerged as a pressing global public health issue, with its prevalence escalating at an unprecedented rate across...

Systemic Lupus Erythematosus Animal Models

Systemic lupus erythematosus (SLE) is a serious, chronic autoimmune disorder characterized by a heterogeneous clinical presentation, in which various organs...

Endometriosis: Animal Models as Tools to Accelerate New Therapeutics

Introduction Endometriosis is a common gynecological condition that significantly impacts the health of women of reproductive age worldwide. Approximately 10%...

Severe Hyperglycemia and Hyperlipidemia Alter Tumor Growth and Immune Profiles in Syngeneic Tumor Models

Studies have demonstrated that obesity can promote cancer progression through mechanisms that include chronic low-grade inflammation. Previous research with diet-induced...

Knowledge Library